Vitamin D deficiency is prevalent in HIV-infected individuals and vitamin D supplementation is proposed according to standard care. This study aimed at characterizing the kinetics of 25(OH)D in a cohort of HIV-infected individuals of European ancestry to better define the influence of genetic and non-genetic factors on 25(OH)D levels. These data were used for the optimization of vitamin D supplementation in order to reach therapeutic targets.
Methods
1,397 25(OH)D plasma levels and relevant clinical information were collected in 664 participants during medical routine follow-up visits. They were genotyped for 7 SNPs in 4 genes known to be associated with 25(OH)D levels. 25(OH)D concentrations were analysed using a population pharmacokinetic approach. The percentage of individuals with 25(OH)D concentrations within the recommended range of 20–40 ng/ml during 12 months of follow-up and several dosage regimens were evaluated by simulation.
Results
A one-compartment model with linear absorption and elimination was used to describe 25(OH)D pharma-cokinetics, while integrating endogenous baseline plasma concentrations. Covariate analyses confirmed the effect of seasonality, body mass index, smoking habits, the analytical method, darunavir/ritonavir and the genetic variant in GC (rs2282679) on 25(OH)D concentrations. 11% of the inter-individual variability in 25(OH)D levels was explained by seasonality and other non-genetic covariates, and 1% by genetics. The optimal supplementation for severe vitamin D deficient patients was 300,000 IU two times per year.
Conclusions
This analysis allowed identifying factors associated with 25(OH)D plasma levels in HIV-infected individuals. Improvement of dosage regimen and timing of vitamin D supplementation is proposed based on those results.
References
1.
AllavenaC., DelpierreC., CuzinL.High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.J Antimicrob Chemother2012; 67: 2222–2230.
2.
BrownT.T., McComseyG.A.Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.Antivir Ther2010; 15: 425–429.
3.
DaoC.N., PatelP., OvertonE.T.Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population.Clin Infect Dis2011; 52: 396–405.
4.
WelzT., ChildsK., IbrahimF.Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.AIDS2010; 24: 1923–1928.
5.
MuellerN.J., FuxC.A., LedergerberB.High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients.AIDS2010; 24: 1127–1134.
6.
HolickM.F., BinkleyN.C., Bischoff-FerrariH.A.Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab2011; 96: 1911–1930.
7.
WangY., ZhuJ., DeLucaH.F.Where is the vitamin D receptor?Arch Biochem Biophys2012; 523: 123–133.
8.
DeLucaH F.. Overview of general physiologic features and functions of vitamin D.Am J Clin Nutr2004; 80: 1689S–1696S.
9.
JonesG.Pharmacokinetics of vitamin D toxicity.Am J Clin Nutr2008; 88: 582S–586S.
10.
JonesK.S., SchoenmakersI., BluckL.J., DingS., PrenticeA.Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults.Br J Nutr2012; 107: 1128–1137.
11.
Brouwer-BrolsmaE.M., Bischoff-FerrariH.A., BouillonR.Vitamin D: do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe.Osteoporos Int2013; 24: 1567–1577.
12.
RosenC.J., AbramsS.A., AloiaJ.F.IOM committee members respond to Endocrine Society vitamin D guideline.J Clin Endocrinol Metab2012; 97: 1146–1152.
13.
ZittermannA., IodiceS., PilzS.Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies.Am J Clin Nutr2012; 95: 91–100.
14.
MichaëlssonK., BaronJ.A., SnellmanG.Plasma vitamin D and mortality in older men: a community-based prospective cohort study.Am J Clin Nutr2010; 92: 841–848.
15.
AhnJ., YuK., Stolzenberg-SolomonR.Genome-wide association study of circulating vitamin D levels.Hum Mol Genet2010; 19: 2739–2745.
16.
Lasky-SuJ., LangeN., BrehmJ.M.Genome-wide association analysis of circulating vitamin D levels in children with asthma.Hum Genet2012; 131: 1495–1505.
17.
WangT.J., ZhangF., RichardsJ.B.Common genetic determinants of vitamin D insufficiency: a genome-wide association study.Lancet2010; 376: 180–188.
18.
SpeeckaertM., HuangG., DelangheJ.R., TaesY.E.Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism.Clin Chim Acta2006; 372: 33–42.
19.
ChengJ.B., LevineM.A., BellN.H., MangelsdorfD.J., RussellD.W.Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase.Proc Natl Acad Sci U S A2004; 101: 7711–7715.
20.
WaterhamH.R., WandersR.J.Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome.Biochim Biophys Acta2000; 1529: 340–356.
21.
JonesG., ProsserD.E., KaufmannM.25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D.Arch Biochem Biophys2012; 523: 9–18.
22.
FoissacF., TreluyerJ.M., SouberbielleJ.C.Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.Br J Clin Pharmacol2013; 75: 1312–1320.
23.
CarrozzaC., PersichilliS., CanuG.Measurement of 25-hydroxyvitamin vitamin D by liquid chromatography tandem-mass spectrometry with comparison to automated immunoassays.Clin Chem Lab Med2012; 50: 2033–2035.
24.
CarterG.D.Accuracy of 25-hydroxyvitamin D assays: confronting the issues.Curr Drug Targets2011; 12: 19–28.
25.
BealS., SheinerL.B., BoeckmannA., BauerR.J.NONMEM User's Guides (1989–2009). Ellicott City, MD, USA: ICON Development Solutions2009.
26.
LindbomL., PihlgrenP., JonssonE.N.PsN-Toolkit–a collection of computer intensive statistical methods for nonlinear mixed effect modeling using NONMEM.Comput Methods Programs Biomed2005; 79: 241–257.
27.
LindbomL., RibbingJ., JonssonE.N.Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming.Comput Methods Programs Biomed2004; 75: 85–94.
28.
BrendelK., CometsE., LaffontC., LaveilleC., MentreF.Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.Pharm Res2006; 23: 2036–2049.
29.
DudbridgeF.Power and predictive accuracy of polygenic risk scores.PLoS Genet2013; 9: e1003348.
30.
BraunA., BichlmaierR., CleveH.Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types.Hum Genet1992; 89: 401–406.
31.
WebbA.R.Who, what, where and when-influences on cutaneous vitamin D synthesis.Prog Biophys Mol Biol2006; 92: 17–25.
32.
SnijderM.B., van DamR.M., VisserM.Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women.J Clin Endocrinol Metab2005; 90: 4119–4123.
33.
WortsmanJ., MatsuokaL.Y., ChenT.C., LuZ., HolickM.F.Decreased bioavailability of vitamin D in obesity.Am J Clin Nutr2000; 72: 690–693.
34.
Cutillas-MarcoE., Fuertes-ProsperA., GrantW.B., Morales-Suarez-VarelaM.Vitamin D deficiency in South Europe: effect of smoking and aging.Photodermatol Photoimmunol Photomed2012; 28: 159–161.
35.
HermannA.P., BrotC., GramJ., KolthoffN., MosekildeL.Premenopausal smoking and bone density in 2015 perimenopausal women.J Bone Miner Res2000; 15: 780–787.
36.
GuptaR.P., HeY.A., PatrickK.S., HalpertJ.R., BellN.H.CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis.J Clin Endocrinol Metab2005; 90: 1210–1219.
37.
GuptaR.P., HollisB.W., PatelS.B., PatrickK.S., BellN.H.CYP3A4 is a human microsomal vitamin D 25-hydroxylase.J Bone Miner Res2004; 19: 680–688.
38.
BrodieM.J., BoobisA.R., DolleryC.T.Rifampicin and vitamin D metabolism.Clin Pharmacol Ther1980; 27: 810–814.
FoxJ., PetersB., PrakashM.Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.AIDS Res Hum Retroviruses2011; 27: 29–34.
JohnsonA.D., HandsakerR.E., PulitS.L.SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap.Bioinformatics2008; 24: 2938–2939.
43.
SafadiF.F., ThorntonP., MagieraH.Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein.J Clin Invest1999; 103: 239–251.
44.
HartP.H., GormanS., Finlay-JonesJ.J.Modulation of the immune system by UV radiation: more than just the effects of vitamin D?Nat Rev Immunol2011; 11: 584–596.
